GIP and type 2 diabetes mellitus: Recently, two novel agents have become available to treat patients with type 2 diabetes: finerenone, a non-steroidal mineralocorticoid receptor antagonist, and tirzepatide, a dual glucose dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist.